Cargando…

Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study

The comparative effectiveness of oral hypoglycemic agents on glycemic control and chronic complications in clinical practice is unknown in Korea. This study aimed to compare glycemic control and the incidence of hypoglycemia and chronic complications among adult patients with type 2 diabetes prescri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Kyung Ae, Jin, Heung Yong, Kim, Yu Ji, Kim, Sang Soo, Cho, Eun-Hee, Park, Tae Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	4300
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878728/ https://www.ncbi.nlm.nih.gov/pubmed/35212277 http://dx.doi.org/10.1097/MD.0000000000028823

Ejemplares similares

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
por: Park, Se Hee, et al.
Publicado: (2016)

Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes: A protocol for systematic review and meta analysis
por: Liu, Shiyu, et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study
por: Lai, Yun-Ju, et al.
Publicado: (2015)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort
por: Kim, Hae Jin, et al.
Publicado: (2018)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes
por: Kim, Jiwoon, et al.
Publicado: (2019)

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
por: Jeon, Won Kyeong, et al.
Publicado: (2021)

Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia
por: Park, Joon Seok, et al.
Publicado: (2021)

Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Jeon, Won Kyeong, et al.
Publicado: (2022)

Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes
por: Lee, Suhrin, et al.
Publicado: (2020)

Causal association of metformin and osteoporosis: A 2-sample Mendelian randomization study
por: Wei, Yong-Kang, et al.
Publicado: (2023)

Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea
por: Cho, Nam-Jun, et al.
Publicado: (2021)

Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
por: Ma, Shujuan, et al.
Publicado: (2017)

Metformin and acupuncture for polycystic ovary syndrome: A protocol for a systematic review and meta-analysis
por: Gao, Yang, et al.
Publicado: (2020)

Efficacy and safety of metformin in the treatment of gestational diabetes: A protocol for systematic review and meta-analysis
por: Mao, Weirong, et al.
Publicado: (2021)

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
por: Seong, Jong-Mi, et al.
Publicado: (2015)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review
por: Zhang, Qing-Qing, et al.
Publicado: (2020)

Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study
por: Wong, Carlos K. H., et al.
Publicado: (2019)

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
por: Wang, Fei, et al.
Publicado: (2017)

Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
por: Wu, Honghua, et al.
Publicado: (2017)

Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
por: Ha, Kyoung Hwa, et al.
Publicado: (2018)

Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
por: Pan, Qingrong, et al.
Publicado: (2016)

Investigation of the metabolic and endocrinological differences between daily and weekly growth hormone replacement therapy, somapacitan, in patients with adult growth hormone deficiency: A real-world pilot study
por: Abe, Ichiro, et al.
Publicado: (2023)

Osmolar-gap in the setting of metformin-associated lactic acidosis: Case report and a literature review highlighting an apparently unusual association
por: Elshafei, Mohamed Nabil, et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy: A nationwide retrospective cohort study
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Li, Mingxing, et al.
Publicado: (2017)

Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis
por: Li, Jian, et al.
Publicado: (2017)

Effects of continuous use of metformin on cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction: A protocol for systematic review and meta-analysis
por: Shen, Chuanwen, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
por: Gamble, John-Michael, et al.
Publicado: (2018)

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
por: Taisiia Pavlovna, Tuchina, et al.
Publicado: (2021)

Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
por: Han, Eugene, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_11fgmi2rgvf6ntqsai9qu3v1vu